141 related articles for article (PubMed ID: 20812347)
21. Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE cell proliferation.
Hecquet C; Lefevre G; Valtink M; Engelmann K; Mascarelli F
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):3091-8. PubMed ID: 12202534
[TBL] [Abstract][Full Text] [Related]
22. Ras/Raf/MEK/ERK pathway is associated with lung metastasis of osteosarcoma in an orthotopic mouse model.
Yu Y; Luk F; Yang JL; Walsh WR
Anticancer Res; 2011 Apr; 31(4):1147-52. PubMed ID: 21508358
[TBL] [Abstract][Full Text] [Related]
23. Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway.
Du W; Zhou JR; Wang DL; Gong K; Zhang QJ
World J Surg Oncol; 2012 Apr; 10():60. PubMed ID: 22520038
[TBL] [Abstract][Full Text] [Related]
24. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Marampon F; Ciccarelli C; Zani BM
Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
[TBL] [Abstract][Full Text] [Related]
25. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.
Llobet D; Eritja N; Yeramian A; Pallares J; Sorolla A; Domingo M; Santacana M; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X
Eur J Cancer; 2010 Mar; 46(4):836-50. PubMed ID: 20071162
[TBL] [Abstract][Full Text] [Related]
26. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
Tran MA; Smith CD; Kester M; Robertson GP
Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
[TBL] [Abstract][Full Text] [Related]
27. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
McCubrey JA; Milella M; Tafuri A; Martelli AM; Lunghi P; Bonati A; Cervello M; Lee JT; Steelman LS
Curr Opin Investig Drugs; 2008 Jun; 9(6):614-30. PubMed ID: 18516761
[TBL] [Abstract][Full Text] [Related]
28. Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways.
Li Q; Wu J; Zheng H; Liu K; Guo TL; Liu Y; Eblen ST; Grant S; Zhang S
Bioorg Med Chem Lett; 2010 Aug; 20(15):4526-30. PubMed ID: 20580230
[TBL] [Abstract][Full Text] [Related]
29. A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway.
Carie AE; Sebti SM
Oncogene; 2007 May; 26(26):3777-88. PubMed ID: 17260025
[TBL] [Abstract][Full Text] [Related]
30. Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo.
Chen C; Zhou H; Xu L; Xu D; Wang Y; Zhang Y; Liu X; Liu Z; Ma D; Ma Q; Chen Y
Apoptosis; 2010 Jul; 15(7):805-13. PubMed ID: 20349137
[TBL] [Abstract][Full Text] [Related]
31. Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling.
Chen J; Shen Q; Labow M; Gaither LA
Cancer Res; 2011 Jun; 71(12):4280-91. PubMed ID: 21527556
[TBL] [Abstract][Full Text] [Related]
32. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
33. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
[TBL] [Abstract][Full Text] [Related]
34. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.
Huether A; Höpfner M; Baradari V; Schuppan D; Scherübl H
Biochem Pharmacol; 2007 May; 73(9):1308-17. PubMed ID: 17266941
[TBL] [Abstract][Full Text] [Related]
35. Raf-1 kinase activation is uncoupled from downstream MEK/ERK pathway in cells treated with Src tyrosine kinase inhibitor PP2.
Lee M
Biochem Biophys Res Commun; 2006 Nov; 350(2):450-6. PubMed ID: 17010316
[TBL] [Abstract][Full Text] [Related]
36. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
37. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.
Lasithiotakis KG; Sinnberg TW; Schittek B; Flaherty KT; Kulms D; Maczey E; Garbe C; Meier FE
J Invest Dermatol; 2008 Aug; 128(8):2013-23. PubMed ID: 18323781
[TBL] [Abstract][Full Text] [Related]
38. Signaling of extracellular inorganic phosphate up-regulates cyclin D1 expression in proliferating chondrocytes via the Na+/Pi cotransporter Pit-1 and Raf/MEK/ERK pathway.
Kimata M; Michigami T; Tachikawa K; Okada T; Koshimizu T; Yamazaki M; Kogo M; Ozono K
Bone; 2010 Nov; 47(5):938-47. PubMed ID: 20709201
[TBL] [Abstract][Full Text] [Related]
39. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.
Messmer D; Fecteau JF; O'Hayre M; Bharati IS; Handel TM; Kipps TJ
Blood; 2011 Jan; 117(3):882-9. PubMed ID: 21079155
[TBL] [Abstract][Full Text] [Related]
40. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance.
McCubrey JA; Abrams SL; Ligresti G; Misaghian N; Wong EW; Steelman LS; Bäsecke J; Troppmair J; Libra M; Nicoletti F; Molton S; McMahon M; Evangelisti C; Martelli AM
Leukemia; 2008 Nov; 22(11):2080-90. PubMed ID: 18685611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
